Evaluation of thyroid cancer in Chinese females with breast cancer by vascular endothelial growth factor (VEGF), microvessel density, and contrast-enhanced ultrasound (CEUS)

Tumor Biology

Volumn 35, Issue 7, 2014, Pages 6521-6529

  Wei, Xi ^a   Li, Ying ^a   Zhang, Sheng ^a   Ming, Gao ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Breast cancer; Chinese females; Contrast enhanced ultrasound (CEUS); Microvessel density; Thyroid cancer; Vascular endothelial growth factor (VEGF)

Indexed keywords

CD34 ANTIGEN; SONOVUE; VASCULOTROPIN;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST CARCINOMA; CAPILLARY DENSITY; CHINESE; CLINICAL ARTICLE; DISTANT METASTASIS; ECHOGRAPHY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MASTECTOMY; PARTIAL MASTECTOMY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; THYROID CANCER; THYROID GLAND; THYROID MEDULLARY CARCINOMA; THYROID PAPILLARY CARCINOMA; THYROIDECTOMY;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD34; ASIAN CONTINENTAL ANCESTRY GROUP; BREAST NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICROVESSELS; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; THYROID NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84904973360     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-014-1868-2     Document Type: Article

References (31)

1. Wei X, Li Y, Zhu Y, Zhang S. Microvascular of breast lesions evaluated by contrast enhancement ultrasound imaging combined with pathologic basis of angiogenesis. Chin J Clinicians. 2011;5:120-4. article in Chinese.
2. Wei X, Li Y, Zhang S, Zhu Y, Fan Y. Experience in large-core needle biopsy in the diagnosis of 1431 breast lesions. Med Oncol. 2011;28:429-33.
3. Eden K, Mahon S, Helfand M. Screening high-risk populations for thyroid cancer. Med Pediatr Oncol. 2001;36:583-91. (Pubitemid 32336566)
4. Hardefeldt PJ, Eslick GD, Edirimanne S. Benign thyroid disease is associated with breast cancer: a meta-analysis. Breast Cancer Res Treat. 2012;133:1169-77.
5. Nio Y, Iguchi C, Itakura M, et al. High incidence of synchronous or metachronous breast cancer in patients with malignant and benign thyroid tumor or tumor-like disorders. Anticancer Res. 2009;29:1607-10.
6. de Gonzalez Berrington A, Curtis RE, et al. Proportion of second cancers attributable to radiotherapy treatment in adults: a cohort study in the US SEER cancer registries. Lancet Oncol. 2011;12:353-60.
7. Houtzager S, Wijkstra H, de la Rosette JJ, Laguna MP. Evaluation of renal masses with contrast-enhanced ultrasound. Curr Urol Rep. 2013;14:116-23.
8. Amarteifio E, Krix M, Wormsbecher S, et al. Dynamic contrast-enhanced ultrasound for assessment of therapy effects on skeletal musclemicrocirculation in peripheral arterial disease: pilot study. Eur J Radiol. 2012;82:640-6.
9. Dǎnilǎ M, Sporea I, Sirli R, Popescu A, Sendroiu M, Martie A. The role of contrast enhanced ultrasound (CEUS) in the assessment of liver nodules in patients with cirrhosis. Med Ultrason. 2010;12:145-9.
10. Xia Y, Jiang YX, Dai Q, Xiao Y, Lv K, Wang L. Contrast-enhanced ultrasound of hepatocellular carcinoma: correlation of washout time and angiogenesis. Clin Hemorheol Microcirc. 2011;48:265-73.
11. Uller W, Jung EM, Hornung M, et al. Evaluation of the microvascularization of pathologic parathyroid glands in patients with primary hyperparathyroidism using conventional ultrasound and contrast-enhanced ultrasound. Clin Hemorheol Microcirc. 2011;48:95-103.
12. Lee SH, Lee SJ, Jin SM, et al. Relationships between lymph node metastasis and expression of CD31, D2-40, and vascular endothelial growth factors A and C in papillary thyroid cancer. Clin Exp Otorhinolaryngol. 2012;5:150-5.
13. Capp C, Wajner SM, Siqueira DR, Brasil BA, Meurer L, Maia AL. Increased expression of vascular endothelial growth factor and its receptors, VEGFR-1 and VEGFR-2 in medullary thyroid carcinoma. Thyroid. 2010;20:863-71.
14. Jebreel A, England J, Bedford K, Murphy J, Karsai L, Atkin S. Vascular endothelial growth factor (VEGF), VEGF receptors expression and microvascular density in benign and malignant thyroid diseases. Int J Exp Pathol. 2007;88:271-7. (Pubitemid 47256303)
15. Saponaro C, Malfettone A, Ranieri G, et al. VEGF, HIF-1α Expression and MVD as an angiogenic network in familial breast cancer. PLoS One. 2013;8:e53070.
16. Chalstrey LJ, Benjamin B. High incidence of breast cancer in thyroid cancer patients. Br J Cancer. 1966;20:670-5.
17. Vassilopoulou-Sellin R, Palmer L, Taylor S, Cooksley CS. Incidence of breast carcinoma in women with thyroid carcinoma. Cancer. 1999;85:696-705. (Pubitemid 29075291)
18. Chen AY, Levy L, Goepfert H, Brown BW, Spitz MR. Vassilopoulou-Sellin R. The development of breast carcinoma in women with thyroid carcinoma. Cancer. 2001;92:225-31. (Pubitemid 32664426)
19. Park JS, Oh KK, Kim EK, Chang HS, Hong SW. Sonographic screening for thyroid cancer in females undergoing breast sonography. AJR Am J Roentgenol. 2006;186:1025-8.
20. Park JS, Oh KK, Kim EK, et al. Sonographic detection of thyroid cancer in breast cancer patients. Yonsei Med J. 2007;48:63-8. (Pubitemid 46403635)
21. Smyth PP. The thyroid, iodine and breast cancer. Breast Cancer Res. 2003;5:235-8. (Pubitemid 37080851)
22. Cenqiz O, Bozkurt B, Unal B, et al. The relationship between prognostic factors of breast cancer and thyroid disorders in Turkish women. J Surg Oncol. 2004;87:19-25. (Pubitemid 38880275)
23. Grani G, Dicorato P, Dainelli M, et al. Thyroid diseases in women with breast cancer. Clin Ter. 2012;163:e401-4.
24. Bartolotta TV, Midiri M, Galia M, et al. Qualitative and quantitative evaluation of solitary thyroid nodules with contrast-enhanced ultrasound: initial results. Eur Radiol. 2006;16:2234-41. (Pubitemid 44349872)
25. Zhang B, Jiang YX, Liu JB, et al. Utility of contrast-enhanced ultrasound for evaluation of thyroid nodules. Thyroid. 2010;20:51-7.
26. Nemec U, Nemec SF, Novotny C, Weber M, Czerny C, Krestan CR. Quantitative evaluation of contrast-enhanced ultrasound after intravenous administration of a microbubble contrast agent for differentiation of benign and malignant thyroid nodules: assessment of diagnostic accuracy. Eur Radiol. 2012;22:1357-65.
27. Huang SM, Lee JC, Wu TJ, Chow NH. Clinical relevance of vascular endothelial growth factor for thyroid neoplasms. World J Surg. 2001;25:302-6.
28. Ramsden JD. Angiogenesis in the thyroid gland. J Endocrinol. 2000;66:475-80.
29. Karpanen T, Egeblad M, Karkkainen MJ, et al. Vascular endo-thelial growth factor C promotes tumor lymphjangiogenesis and intralymphatic tumor growth. Cancer Res. 2001;61:1786-90. (Pubitemid 32691984)
30. Lewy-Trenda I, Wierzchniewska-Lawska A. Expression of vascular endothelial growth factor (VEGF) in human thyroid tumor. Pol J Pathol. 2002;53:129-32. (Pubitemid 35278474)
31. Fenton C, Patel A, Dinauer C, Robie DK, Tuttle RM, Francis GL. The expression of vascular endothelial growth factor and the type 1 vascular endothelial growth factor receptor correlate with the size of papillary thyroid carcinoma in children and young adults. Thyroid. 2000;10:349-57. (Pubitemid 30256865)